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mmHg and 28*8 mmHg (p=O.528); systolic blood pressure 98+13mmHg and 
99+18mmHg (p=O.839); cardiac index 2.2+0.71Vmin/m2 and 2.1+0.61t/min/m2 (p=O.719). 
Kaplan-M&r sul~wal analysis showed a 60% reduction in the risk of death from any 
cause in the group treated with the combination of dobutemine and amiodarone, com- 
pared with the group treated with placebo and amiodarone (hazard ratio 0.403; 95% con- 
fidence interval 0.164-0.992, p=O.O48). The 1. and P-year survival rates were 69% and 
44%, in the dobutamine-treated group, versus 28% and 21%, respectively, in the pla- 
cebo-treated group (pcO.05 for both comparisons). Median su~lvals were 574 and 144 
days in Groups 2 and 1, respectively. At six months,‘the NYHA functional class was sig- 
nificantly Improved in the surviving patients of both groups. Conclusion: Long-term IDI 
combined with amiodarone, added to conventional treatment, improves survival of 
patients with severe CHF. 
the magnitude of that benefit is signficantly less than that observed in non-DM CHF pts. 
Therefore, all eligible pts wth symptomatic CHF, regardless of their DM status, should 
receive BBS for their prognostic benefits. 
All-Cause Mortabty: Diabetic vs Non-Diabetic Patients 
1085-76 Statin Therapy Is Associated With Improved Survival in 
lschemic and Nonischemic Heart Failure 
Tamara 8. Horwich, Michele A. Hamilton, Robb MacLellan, Jignesh Patel, Mary 
Lesniewski, Gregg C. Fonarow. University of California Los Angeles Medical Center, Los 
Angeles, CA 
Study 
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Total 
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N RR 95% Cl r; RR 95% Cl 
964 0.95 0.80, 1.12 1744 0.89 0.77, 1.02 
307 0.37 0.14,0.93 772 0.44 0.23, 0.86 
312 0.81 0.52. 1.27 2335 0.68 0.55, 0.82 
589 0.68 0.46, 0.99 1700 0.67 0.53, 0.85 
984 0.82 0.58, 1.17 3007 0.58 0.46, 0.74 
3156 0.85 0.74,0.97 9558 0.72 0.65, 0.79 
1085-78 
Background: Although HMG CoA reductase inhibitors (statins) are known to decrease 
mortality in CHD, concern has been raised about potential negative effects in patients 
with heart failure (HF). The impact of statins on the progression of advanced HF has not 
been studied. 
Electrophysiologic Alterations Seen in Patients With 
Advanced Cardiac Failure After Angiotension 
Converting Enzyme Inhibitor Therapy 
Methods: We retrospectively studied a cohort of 251 pts with advanced HF referred for 
management and transplant evaluation. Pts without adequate documentation of medical 
regimen (n=33) were excluded from analysis. Survival free from death or urgent trans- 
plant was determined. 
Results: Mean age, EF, and total cholesterol (TC) were 52,25%, and 165 mg/dl, respec- 
tively. Fifty-one % of pts were on statin Rx. CAD was etiology of HF in 52% of patients, 
79% of whom were on statin Rx. In non-CAD HF pts. 28% were on statin Rx. Pis on 
statins were significantly older, and had higher rates of CAD, smoking, HTN, and DM. 
Treated and non-treated pts were similar in NYHA. LVEF, sex. BMI, TC, and HF medica- 
tions. Pts on statin Rx had improved survival over a 22 month follow-up (74% vs 56%, 
p=O.OOS). In subsets of pts without CAD and with TC cl65 mgidl. statins were similarly 
associated with Improved survival (p=O.O06. p=O.O4 respectively). Statin Rx was an inde- 
pendent predictor of improved survival after risk-adjustment for age. sex, EF, ACEI Rx. 
renal function, and serum cardiac troponin I. 
Petra S. Niemann, Roben Robbins, Julie Shinn, L. Bing Lien?, Sung Chun, Karen J 
Friday, Stanford University, Stanford, CA 
Background: Recognlzmg that mechanical circulatoty support induces changes in myo- 
cardial contractile function and intraventricular conduction (lVC),we examined whether 
there are changes iki IVC among heart failure patients with medical therapy only. Meth- 
ods: We studied 85 consecutive patients with New York Heart Association (NYHA) class 
2 and 3 heart failure undergoing medical therapy with ACE-Inhibitors and Beta-Blockers. 
Mean follow-up bme was 452 d +/- 186( median 374 d. range 128 to 745 d). Doppler 
Echocardiograms, ECGs and clinical symptom evaluations (NYHA) were obtained in 3 to 
6 months intewalls. Results: OF 85 oatients. 79 192%) showed IVC imorovement on cur- 
face ECG following medical therapy initiation (p< 0.01). Measured effects included a 
decrease in QRS duration from 115+/- 8 to 102 +I- 6 ms lo< 0.011 a decrease in absolute 
Conclusions: Statin Rx was associated with improved survival in ischemic and non- 
ischemic HF. Randomized trials are needed for confirmation of therapeutic benefit in 
non-ischemic HF. 
QT duration from 398 +/- 12 ms to 348 +I- 7 ms (p< 0.01) and a decrease in heart rate 
from 100.6 +/- 22.6 to 65 +/-I2 ms (p< 0.01). A LBBB pattern observed in 
32(37%)patlents prior to treatment initiation resolved in 14 (43%) patients after 6 months 
of medical therapy (p-z 0.01). Improved IVC on surface ECG and echocardlographic 
changes in myocardial structure and contractile function were positively correlated. (p-z 
0.01). All echocardlographic and electrocardiographic findings could be positivly corre- 
lated with clinical symptom improvement (NYHA class 1 and 2) in 83 ( 97%) patients (p-z 
0.01). Conclustions: Electrocardiographic changes seen with medical therapy aimed to 
improve myocardial contractility in heart failure patients demonstrate that IVC and repo- 
larization are dependent on longterm myocyte contractile function and possibly on 
altered calcium homeostasis. Improved left ventricular conduction and shortened cardiac 
action potential seen with ACE-Inhibitors therapy in heart failure seems therefore rather a 
longstanding Ion channel dependent process implicating variable gene expression in the 
failing heart than a pure mechanical response to hemodynamic loading conditions of the 
left ventricle. 
1085-77 Does the Magnitude of the Beneficial Effect of Beta- 
Blockers in Chronic Heart Failure Differ Between 
Diabetic and Nondiabetic Patients? A Meta-Analysis of 
All-Cause Mortality Outcomes From Major Chronic 
Heart Failure Beta-Blocker Trials 
Steven Haas, Theo Vos, Richard Gilbert, Henn/ Krum, Monash University, Melbourne, 
Australia 
Background: Diabetes mellitus (DM) is a frequent co-motiid association of patients (pts) 
with chronic heart failure (CHF). Although CHF pts derive benefit from beta-blockers 
(BBS), these agents are still thought by many to be contraindicated amongst DM pts and 
definitive data is lacking within this sub-group. We therefore performed a meta-analysis 
of major BB CHF trials to determine the benefits (or othenvise) of BBS in DM pts with 
CHF. 
Methods: All-cause mortality data concernmg DM pts were obtained from all completed 
CHF trials of >lOOO pts randomised to BB or placebo. Trials were identified via MEDLINE 
literature searches, manual reference checks & reference texts. Results were pooled 
using the ManteCHaenszel method. 
Results: 24.8% of pts were reported as having DM in the studies analyzed. DM pts had 
increased mortakty overall c.f. non-DM pts (annualised placebo mortality rate: DM 
17.0%. non-DM 13.9%; RR: 1.22, 95% Cl: 1.07-1.39). The Impact of BBS on mortality is 
summarised in the Table. 
BBS for CHF appears to be clinically beneficial I” DM es well as non-DM pts. However, 
the benficial impact of BBS is significantly greeter in non-DM pts, by calculation of risk dif- 
ference (PcO.05). 
Discussion: CHF pts wth DM appear to derive prognostic benefit from BBS, even though 
1085-79 Sustained Hemodynamic Benefit During Long-Term 
Positive lnotropic Infusion in Patients With Advanced 
Heart Failure 
Shnkanth P. Upadva. Forrester A. Lee, Clara I. Saldarriaga. Karin Nystrom, Stuart D. 
Katz, Yale University, New Haven, CT 
Background: Long term intravenous inotropic therapy is used as a bridge to cardiac 
transplantation in patients with end-stage chronic heart failure (CHF). We aimed to deter- 
mine whether acute hemodynamic benefits were sustained during chronic therapy. 
Methodr:We analyzed serial hemodynamic data from Plpatients with advanced CHF 
(mean age 55 ys, LVEF 21%) listed for cardiac transplantation and treated with continu- 
ous home infusions of positive inotropic agents. Rest hemodynamic data before, and at 
24 hours and 3-6 months after initiation of positive inotropic therapy were compared. Ino- 
tropic agent was dobutemine in 12 subjects (mean dose 4.5 mcglkglmin. range 2.5-7.5 
mcglkglmin), milrinone in 8 subjects (mean dose 0.44 mcglkglmin, range 0.375-0.55 mcl 
kglmin), and dopamine 3 mcg&$min in 1 subject. Oral neurohormonal antagonists were 
given es tolerated. Diuretics were adjusted to maintain a non-edematous state. 
Results: lnotropic therapy acutely improved rest hemodynamics charactewed by 
decreased PA pressure, PCWP and PVR and increased cardiac index (Table). During 
chronic therapy, further reductions in PA pressure and PVR were observed without 
change in PCWP or cardiac index. 
Conclusion: Acute beneficial hemodynamic effects of positive motropic therapy were 
sustained during chronic therapy in patients with advanced CHF awatlng cardiac trans- 
plantation. Tachyphylaxis was not a clinically important factor limiting the use of continu- 
ous positive inotropic agents in these patients. 
Rcstmg bemodynamics before and during positive inotmpx infusmn 
Right Pulmonary Pulmonary Pulmonary cardiac 
atrial artey mean caplillary wedge vascualr Index 
pressure (PAM) mm pressure resistance(PVR) (Cl) I/mn/ 
(RA) Hg (PCWP) wood units In2 
mm Hg 
